- Stocks
- Pharma & Healthcare
- Abbott India
Abbott India share price
NSE: ABBOTINDIAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Abbott India at a glance
Abbott India (NSE: ABBOTINDIA) closed at ₹25,895.00 on 21 Oct 2026. With a market capitalisation of ₹55,705 Cr, it ranks 172nd by market cap among the 3,928 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 33.4% in FY25. Its 52-week range is ₹25,135.00 (11 Sep 2026) to ₹30,655.00 (25 Nov 2025); the last close is 15.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1,710 Cr (+6.5% year on year) and net profit ₹395 Cr (+7.6%), on a standalone basis. Promoters held 74.99% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹55,705 CrRank 172 on NSE
- Price to book
- 15.43×FY25
- EPS (TTM)
- ₹730.36to Q4 FY26
- ROE
- 33.4%FY25
- ROCE
- 42.1%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 22.1%FY25
- Book value / share
- ₹1,992.07FY25
- Dividend payout
- 61.6%FY25
- 52-week high
- ₹30,655.0025 Nov 2025
- 52-week low
- ₹25,135.0011 Sep 2026
Returns to —
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Abbott India quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,558 Cr | ₹1,633 Cr | ₹1,614 Cr | ₹1,605 Cr | ₹1,738 Cr | ₹1,757 Cr | ₹1,724 Cr | ₹1,710 Cr |
| Revenue YoY | +5.3% | +9.3% | +12.3% | +11.5% | +11.6% | +7.6% | +6.8% | +6.5% |
| Net profit | ₹328 Cr | ₹359 Cr | ₹361 Cr | ₹367 Cr | ₹366 Cr | ₹415 Cr | ₹376 Cr | ₹395 Cr |
| Net profit YoY | +13.0% | +14.6% | +16.0% | +27.9% | +11.5% | +15.8% | +4.2% | +7.6% |
| Net margin | 21.1% | 22.0% | 22.3% | 22.9% | 21.0% | 23.6% | 21.8% | 23.1% |
| EPS | ₹154.36 | ₹168.76 | ₹169.78 | ₹172.72 | ₹172.17 | ₹195.42 | ₹176.92 | ₹185.85 |
Abbott India financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹4,093 Cr | ₹4,310 Cr | ₹4,919 Cr | ₹5,349 Cr | ₹5,849 Cr | ₹6,409 Cr |
| Operating profit | ₹803 Cr | ₹926 Cr | ₹1,080 Cr | ₹1,274 Cr | ₹1,618 Cr | ₹1,887 Cr |
| Net profit | ₹593 Cr | ₹691 Cr | ₹799 Cr | ₹949 Cr | ₹1,201 Cr | ₹1,414 Cr |
| EPS (₹) | ₹279.04 | ₹325.04 | ₹375.86 | ₹446.78 | ₹565.28 | ₹665.62 |
| Cash from operations | ₹626 Cr | ₹727 Cr | ₹948 Cr | ₹893 Cr | ₹1,213 Cr | ₹1,012 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹2,432 Cr | ₹2,602 Cr | ₹2,820 Cr | ₹3,189 Cr | ₹3,699 Cr | ₹4,233 Cr |
Abbott India shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% |
| Foreign institutions | 0.16% | 0.16% | 0.16% | 0.18% | 0.26% | 0.38% |
| Domestic institutions | 8.92% | 9.19% | 9.11% | 9.00% | 8.93% | 8.78% |
| Non-institutions | 15.93% | 15.66% | 15.75% | 15.83% | 15.81% | 15.85% |
Abbott India vs peers
The listed Pharma & Healthcare companies nearest to Abbott India by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BIOCONBiocon | — | — | — | ₹67,290 Cr | — | — |
| ALKEMAlkem Laboratories | — | — | — | ₹64,248 Cr | — | — |
| GLENMARKGlenmark Pharmaceuticals | — | — | — | ₹62,467 Cr | — | — |
| ABBOTINDIAAbbott India | — | — | — | ₹55,705 Cr | — | — |
| ANTHEMAnthem Biosciences | — | — | — | ₹44,434 Cr | — | — |
| ASTERDMAster DM Health | — | — | — | ₹41,841 Cr | — | — |
| IPCALABIPCA Laboratories | — | — | — | ₹40,232 Cr | — | — |
Ask anything about Abbott India
Pivot answers on the live chart with evidence you can check, and tests strategies against ABBOTINDIA's own history. Try: “Why has ABBOTINDIA moved over the last three months?” · “Backtest a 50-day moving-average crossover on ABBOTINDIA over five years” · “Compare ABBOTINDIA with BIOCON on margins and valuation”
Frequently asked questions about Abbott India
What is the share price of Abbott India today?
Abbott India (NSE: ABBOTINDIA) last closed at ₹25,895.00 on 21 Oct 2026. Its 52-week high is ₹30,655.00 and its 52-week low is ₹25,135.00.
What is the market cap of Abbott India?
Abbott India's market capitalisation is ₹55,705 Cr (₹55,705 Cr) at the — close, ranking 172nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Abbott India?
Return on equity was 33.4% in FY25 and return on capital employed was 42.1% in FY25 (standalone figures).
Is Abbott India a debt-free company?
Abbott India is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Abbott India's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Abbott India reported revenue of ₹1,710 Cr, +6.5% year on year, and net profit of ₹395 Cr, +7.6% year on year.
What is the shareholding pattern of Abbott India?
As of 30 Jun 2026: promoters 74.99%, foreign institutions 0.38%, domestic institutions 8.78%, non-institutions 15.85%.
Who are Abbott India's competitors?
The listed Pharma & Healthcare companies closest to Abbott India by market cap are Biocon, Alkem Laboratories, Glenmark Pharmaceuticals, Anthem Biosciences, Aster DM Health and IPCA Laboratories.
Is Abbott India a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Abbott India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ABBOTINDIA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026. Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 3,928 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text